✦ LIBER ✦

Duration of mitosis and diurnal rhythm of cell division of ehrlich's tumor and lymphoma NK/Ly

✍ Scribed by K. G. Moskalik

Publisher: Springer US
Year: 1973
Tongue: English
Weight: 252 KB
Volume: 75
Category: Article
ISSN: 0007-4888
DOI: 10.1007/bf00784701

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Duration of mitosis and diurnal rhythm o

Duration of mitosis and diurnal rhythm of mitotic activity

✍ Yu. A. Romanov; V. P. Rybakov 📂 Article 📅 1970 🏛 Springer US 🌐 English ⚖ 250 KB

Dynamics of phases of mitosis and relati

Dynamics of phases of mitosis and relative duration of cell division

✍ V. N. Dobrokhotov; V. S. Valvas 📂 Article 📅 1981 🏛 Springer US 🌐 English ⚖ 260 KB

Cell division and changes in the duratio

Cell division and changes in the duration of mitosis in Ehrlich's ascites mouse carcinoma after single exposure to chalone-containing extract from this tumor

✍ Yu. A. Romanov; M. V. Semenova 📂 Article 📅 1982 🏛 Springer US 🌐 English ⚖ 255 KB

Comparative action of inhibitor and stim

Comparative action of inhibitor and stimulator in Ehrlich's ascites tumor cells on cell division in the tumor

✍ N. Ya. Matsak; Yu. A. Romanov; A. I. Antokhin 📂 Article 📅 1983 🏛 Springer US 🌐 English ⚖ 252 KB

Effect of propranolol on/mitosis-inhibit

Effect of propranolol on/mitosis-inhibitory activity of G2-chalone and adrenalin in Ehrlich's ascites tumor cell culture

✍ A. I. Antokhin; N. Ya. Popova; D. S. Gembitskii; Yu. A. Romanov 📂 Article 📅 1991 🏛 Springer US 🌐 English ⚖ 169 KB

Simultaneous targeting of IL2 and IL12 t

Simultaneous targeting of IL2 and IL12 to Hodgkin's lymphoma cells enhances activation of resting NK cells and tumor cell lysis

✍ Andreas Hombach; Claudia Heuser; Hinrich Abken 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 139 KB

## Abstract Hodgkin's disease (HD) is characterized by the accumulation of functionally anergic T cells in the vicinity of the malignant Hodgkin/Reed‐Sternberg (H/RS) cells. To revert cellular anergy against H/RS cells, we generated an anti‐CD30‐antibody‐interleukin‐(IL)‐2 and an anti‐CD30‐antibody